Genmab — August 2019

[E_L]

GSK2857916) on track for regulatory submission by the end of 2019 https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-headline-results-from-the-pivotal-dreamm-2-study-for-multiple-myeloma/

[E_L]

New trial in Korea Daratumumab With DCEP for Multiple Myeloma With Plasmacytoma (Dara_DCEP) https://www.clinicaltrials.gov/ct2/show/NCT04065308?term=daratumumab+OR+ofatumumab+OR+arzerra+OR+darzalex+OR+tisotumab+OR+Genmab&lupd_s=08%2F22%2F2019&rank=2

[E_L]

Multiple myeloma is not confined to a specific bone or location within a bone. It tends to involve the entire skeleton. When only one lesion is found it is called a “plasmacytoma.” Most doctors believe that plasmacytoma is simply an early, isolated form of multiple myeloma.

[E_L]

New trial in Israel - Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients (KyDaR) - https://www.clinicaltrials.gov/ct2/show/NCT04065789?term=daratumumab+OR+ofatumumab+OR+arzerra+OR+darzalex+OR+tisotumab+OR+Genmab&lupd_s=08%2F22%2F2019&rank=4

[Sukkeralf]

Impressive planning for GSK2857916 - a lot head to head studies

[E_L]

yes, maybe they learned from their Ofatumumab f*** up....

[Helge_LarsenPI-redaktør]

Bergenbio oppe med 25% og stigende.

[Helge_LarsenPI-redaktør]

30%

[Sukkeralf]

Yes but bold to do head to head - they must believe quite strongly in the BCMA ADC

[Sukkeralf]

Nice Helge

[Helge_LarsenPI-redaktør]

Børsstop.

[Bulder]

In none of the studies dara is a combo-partner. Only opponent in dreamm 7. Could be a compo partner in dreamm 10 though.

[Sukkeralf]

Yes a bit strange Bulder - Jan has mentioned several times that the BCMA target could be combined with daratumumab. And looking at daratumumabs position its very strange that they dont partner up

[Bulder]

Maybe they await Janssen to come up with and finance a study.

[Sukkeralf]

A wild spekulation could be that Janssen dont wat to give them sc dosing of dara because they would combine it with either their CAR-T BCMA or CD3/BCMA. And GSK will not use IV dosing because it will be old fashion in a couple of years

[Sukkeralf]

So until sc dosing is approved GSK must wait

[bibob]

Sounds right Sukker.

[E_L]

we need a GSK Q&A @Helge

[Helge_LarsenPI-redaktør]

[bibob]

Yes E L. And a chat about good Wine and food when we have got good news on a friday with Big raise for Genmab.